Literature DB >> 7554118

High- and low-affinity sites for [3H]dofetilide binding to guinea pig myocytes.

H J Duff1, Z P Feng, R S Sheldon.   

Abstract

Dofetilide specifically blocks the rapid component of the delayed rectifier current (IKr) at nanomolar concentrations in a saturable manner, suggesting the presence of a receptor. We characterized two [3H]dofetilide binding sites to ventricular myocytes from adult guinea pigs by using a conventional filter assay. Scatchard analysis revealed two binding sites with different affinities: a high-affinity site (Kd, 2.8 +/- 0.3 x 10(-8) mol/L; Bmax, 76 +/- 15 fmol/10(6) myocytes) and a low-affinity site (Kd, 1.64 +/- 0.4 x 10(-6) mol/L; Bmax, 1620 +/- 260 fmol/10(6) myocytes) (n = 11). Kinetic studies showed that there were two dissociation rate constants for [3H]dofetilide (0.02 +/- 0.005 min-1 [high-affinity site] and 0.22 +/- 0.064 min-1 [low-affinity site], n = 4), although the observed association rate constant is equally well fit to a single- or two-site model. The ability of known IKr blockers to compete with [3H]dofetilide binding to both sites was assessed. E4031, clofilium, quinidine, and sotalol competed for binding at both sites. Disopyramide and NAPA only competed for a single binding site. The mean IC50 values for inhibition of binding to both the high- and low-affinity binding sites correlated with their concentrations required to inhibit IKr in electrophysiological studies. However, inhibition of [3H]dofetilide binding to the high-affinity site by class III antiarrhythmic drugs occurred at pharmacological concentrations, whereas suprapharmacological concentrations were required to inhibit binding to the low-affinity site.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7554118     DOI: 10.1161/01.res.77.4.718

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  6 in total

Review 1.  Dofetilide: a review of its use in atrial fibrillation and atrial flutter.

Authors:  K J McClellan; A Markham
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  The Pore-Lipid Interface: Role of Amino-Acid Determinants of Lipophilic Access by Ivabradine to the hERG1 Pore Domain.

Authors:  Laura Perissinotti; Jiqing Guo; Meruyert Kudaibergenova; James Lees-Miller; Marina Ol'khovich; Angelica Sharapova; German L Perlovich; Daniel A Muruve; Brenda Gerull; Sergei Yu Noskov; Henry J Duff
Journal:  Mol Pharmacol       Date:  2019-06-10       Impact factor: 4.436

3.  Assessing hERG1 Blockade from Bayesian Machine-Learning-Optimized Site Identification by Ligand Competitive Saturation Simulations.

Authors:  Mahdi Mousaei; Meruyert Kudaibergenova; Alexander D MacKerell; Sergei Noskov
Journal:  J Chem Inf Model       Date:  2020-11-16       Impact factor: 4.956

4.  Stereoselective Blockage of Quinidine and Quinine in the hERG Channel and the Effect of Their Rescue Potency on Drug-Induced hERG Trafficking Defect.

Authors:  Meng Yan; Pan Fan; Yanhui Shi; Lifang Feng; Junnan Wang; Ge Zhan; Baoxin Li
Journal:  Int J Mol Sci       Date:  2016-09-28       Impact factor: 5.923

5.  A multiscale computational modelling approach predicts mechanisms of female sex risk in the setting of arousal-induced arrhythmias.

Authors:  Pei-Chi Yang; Laura L Perissinotti; Fernando López-Redondo; Yibo Wang; Kevin R DeMarco; Mao-Tsuen Jeng; Igor Vorobyov; Robert D Harvey; Junko Kurokawa; Sergei Y Noskov; Colleen E Clancy
Journal:  J Physiol       Date:  2017-06-14       Impact factor: 5.182

6.  Molecular determinants of pro-arrhythmia proclivity of d- and l-sotalol via a multi-scale modeling pipeline.

Authors:  Kevin R DeMarco; Pei-Chi Yang; Vikrant Singh; Kazuharu Furutani; John R D Dawson; Mao-Tsuen Jeng; James C Fettinger; Slava Bekker; Van A Ngo; Sergei Y Noskov; Vladimir Yarov-Yarovoy; Jon T Sack; Heike Wulff; Colleen E Clancy; Igor Vorobyov
Journal:  J Mol Cell Cardiol       Date:  2021-05-29       Impact factor: 5.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.